March 08, 2019

Cerebral Therapeutics Raises Series A Extension Financing to Advance Clinical-Stage Drug Device Combination Therapy to Phase 3 Readiness for Adult Refractory Epilepsy

March 08, 2019/ Distill

Financing Led by Granite Point Capital and Vivo Capital
Cerebral Therapeutics Prepares IND and Clinical Development Program in the U.S.

Aurora, CO., March 8, 2019

Read Full Article

June 20, 2018

Cerebral Therapeutics Raises Series A Financing to Advance Clinical-Stage Drug-Device Combination Therapy for Adult Refractory Epilepsy

June 20, 2018/ Distill

Financing Led by Granite Point Capital and Vivo Capital
Cerebral Therapeutics Adds Three New Members to its Board of Directors

Aurora, CO., June 20, 2018

Read Full Article

October 13, 2017

Flowonix Medical and Cerebral Therapeutics Announce Fifth Implant of First-of-a-Kind Implantable Drug Therapy to Treat Patients with Refractory Epilepsy

October 13, 2017/ Distill

Read Full Article

March 01, 2017

World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy

March 01, 2017/ Distill

Read Full Article

October 01, 2015

Flowonix, Cerebral Therapeutics ink deal to develop direct-to-brain drug delivery system

October 01, 2015/ Distill

Read Full Article